© 2000 by European Society of Cardiology
Copyright © 2000, European Society of Cardiology
Cardiotrophin-1 protects the human myocardium from ischemic injury
Comparison with the first and second window of protection by ischemic preconditioning
aDivision of Cardiac Surgery, Department of Surgery, University of Leicester, Glenfield Hospital, Leicester LE3 9QP, UK
bDepartment of Medicine and Therapeutics, University of Leicester, Leicester Royal Infirmary, Leicester LE1 5WW, UK
* Corresponding author. Fax: +44-116-232-1282 sudip.ghosh{at}glenfield-tr.trent.nhs.uk
Background: There are reports suggesting that cardiotrophin 1 (CT-1) is cytoprotective. We investigated the cardioprotective effects of CT-1 on the human myocardium and compared this benefit with the early and delayed protection afforded by ischemic preconditioning (PC). Methods: Right atrium specimens were prepared and incubated in buffer solution at 37°C for 30 min stabilisation, before entering one of the three following studies. In study 1, muscles (n = 6/group) were allocated to one of four groups: (i) aerobic control — incubated in oxygenated media for 210 min, (ii) ischemia alone — 90 min ischemia followed by 120 min reoxygenation, (iii) PC by 5 min ischemia–5 min reoxygenation before 90 min ischemia–120 min reoxygenation and (iv) CT-1 (1 nM) — 90 min ischemia–120 min reoxygenation with exposure to CT-1 throughout the protocol. In study 2, muscles (n = 6/group) were allocated to one of four protocols as in study 1with the exception that were incubated for 24 h followed by 30 or 90 min ischemia–120 min reoxygenation on day 2. In study 3, the same groups were employed as in study 2 with the exception that only a 30-min period of ischemia was used and that CT-1 antibody (5 µg/ml) was added to all groups throughout the experimental protocol. Creatine kinase (CK, U/g wet wt.) leakage into the medium and MTT reduction (OD/mg wet wt.), an index of cell viability, were assessed at the end of the experiment. Results: In study 1, a first window of cardioprotection was observed with PC (CK=4.39±0.34; MTT=0.58±0.03 vs. CK=7.11±0.4;MTT=0.32±0.02 in the ischemic alone group; P<0.001) but not with CT-1(CK=6.65±0.67; MTT=0.31±0.03, P = NS vs. ischemia alone). In study 2, PC applied on day 1 was protective against 30-min ischemia (CK=3.28±0.43; MTT=0.68±0.046, P<0.001 vs. ischemia alone) but not against 90-min ischemia (CK=7.13±0.66; MTT=0.24±0.03, P = NS vs. ischemia alone) induced on day 2 (second window). However, when the tissue was exposed to CT-1 for 24 h, protection was similar to that of PC when subjected to 30 min of ischemia (CK=2.95±0.71; MTT=0.77±0.05, P = NS vs. PC) and greater than PC when subjected to 90 min of ischemia (CK=4.56±0.51; MTT=0.39±0.03, P = 0.002 vs. PC). In study 3, the CT-1 antibody did not affect the protection induced by PC (CK=3.36±0.6; MTT=0.69±0.06) but it abolished the protection obtained with CT-1(CK=5.15±0.81; MTT=0.42±0.06, P = NS vs. ischemia alone group). Conclusions: CT-1 exhibits a significant protection of the human myocardium against ischemic injury when tissue is exposed to this factor for a long period (e.g. 24 h) but not when exposed for a short period (e.g. 2 h). In addition, the protection afforded by long exposure to CT-1 is as potent or even greater than the one obtained by the second window of PC. The protection induced by CT-1 but not that induced by PC can be abolished by CT-1 antibody suggesting that their beneficial action is attained by different mechanisms.
KEYWORDS Hypoxia/anoxia; Preconditioning
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  D. J. Hausenloy and D. M. Yellon Cardioprotective growth factors Cardiovasc Res, July 15, 2009; 83(2): 179 - 194. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Ichiki, M. Jougasaki, M. Setoguchi, J. Imamura, H. Nakashima, T. Matsuoka, M. Sonoda, K. Nakamura, S. Minagoe, and C. Tei Cardiotrophin-1 stimulates intercellular adhesion molecule-1 and monocyte chemoattractant protein-1 in human aortic endothelial cells Am J Physiol Heart Circ Physiol, February 1, 2008; 294(2): H750 - H763. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Lopez, J. M. Castellano, A. Gonzalez, J. Barba, and J. Diez Association of Increased Plasma Cardiotrophin-1 With Inappropriate Left Ventricular Mass in Essential Hypertension Hypertension, November 1, 2007; 50(5): 977 - 983. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. A. Petersen, K. A. Krumholz, J. Carmen, A. P. Sinai, and B. A. Burleigh Trypanosoma cruzi Infection and Nuclear Factor Kappa B Activation Prevent Apoptosis in Cardiac Cells Infect. Immun., March 1, 2006; 74(3): 1580 - 1587. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. A. Petersen, K. A. Krumholz, and B. A. Burleigh Toll-Like Receptor 2 Regulates Interleukin-1{beta}-Dependent Cardiomyocyte Hypertrophy Triggered by Trypanosoma cruzi Infect. Immun., October 1, 2005; 73(10): 6974 - 6980. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. J. Pemberton, S. D. Raudsepp, T. G. Yandle, V. A. Cameron, and A. M. Richards Plasma cardiotrophin-1 is elevated in human hypertension and stimulated by ventricular stretch Cardiovasc Res, October 1, 2005; 68(1): 109 - 117. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. H. Freed, R. H. Cunnington, A. L. Dangerfield, J. S. Sutton, and I. M.C. Dixon Emerging evidence for the role of cardiotrophin-1 in cardiac repair in the infarcted heart Cardiovasc Res, March 1, 2005; 65(4): 782 - 792. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J Hausenloy and D. M Yellon New directions for protecting the heart against ischaemia-reperfusion injury: targeting the Reperfusion Injury Salvage Kinase (RISK)-pathway Cardiovasc Res, February 15, 2004; 61(3): 448 - 460. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Nomura, M. Asano, T. Saito, S. Sasaki, H. Suzuki, T. Manabe, and A. Mishima Cardiotrophin-1 is a prophylactic against the development of chronic hypoxic pulmonary hypertension in rats Ann. Thorac. Surg., July 1, 2003; 76(1): 237 - 243. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Liao, B. K. Brar, Q. Cai, A. Stephanou, R. M. O'Leary, D. Pennica, D. M. Yellon, and D. S. Latchman Cardiotrophin-1 (CT-1) can protect the adult heart from injury when added both prior to ischaemia and at reperfusion Cardiovasc Res, March 1, 2002; 53(4): 902 - 910. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Tsuruda, M. Jougasaki, G. Boerrigter, B. K. Huntley, H. H. Chen, A. B. D'Assoro, S. C. Lee, A. M. Larsen, A. Cataliotti, and J. C. Burnett Jr Cardiotrophin-1 Stimulation of Cardiac Fibroblast Growth: Roles for Glycoprotein 130/Leukemia Inhibitory Factor Receptor and the Endothelin Type A Receptor Circ. Res., February 8, 2002; 90(2): 128 - 134. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. R Holleyman and D. F Larson Apoptosis in the ischemic reperfused myocardium Perfusion, December 1, 2001; 16(6): 491 - 502. [Abstract] [PDF]
|
|
|
|
|
|
T. Tsuruda, M. Jougasaki, G. Boerrigter, B. K. Huntley, H. H. Chen, A. B. D'Assoro, S. C. Lee, A. M. Larsen, A. Cataliotti, and J. C. Burnett Jr Cardiotrophin-1 Stimulation of Cardiac Fibroblast Growth: Roles for Glycoprotein 130/Leukemia Inhibitory Factor Receptor and the Endothelin Type A Receptor Circ. Res., February 8, 2002; 90(2): 128 - 134. [Abstract] [Full Text] [PDF]
|
|